WEST PHARMACEUTICAL SERVICES, INC. Segment Expenditure Addition To Long Lived Assets
WEST PHARMACEUTICAL SERVICES, INC. (WST) reported Segment Expenditure Addition To Long Lived Assets of $43.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Notes › Segment Reporting
us-gaap:SegmentExpenditureAdditionToLongLivedAssets · last filed 2026-07-23
- WEST PHARMACEUTICAL SERVICES, INC. segment expenditure addition to long lived assets for the quarter ending 2026-06-30 was $43.20M, a 42.55% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. segment expenditure addition to long lived assets for the quarter ending 2026-03-31 was $42.70M, a 40.11% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. segment expenditure addition to long lived assets for the quarter ending 2025-12-31 was $76.10M, a 27.45% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. segment expenditure addition to long lived assets for the quarter ending 2025-09-30 was $63.30M, a 22.14% decline year-over-year.
- WEST PHARMACEUTICAL SERVICES, INC. segment expenditure addition to long lived assets for fiscal 2025 was $285.90M, a 24.16% decline from fiscal 2024.
- WEST PHARMACEUTICAL SERVICES, INC. segment expenditure addition to long lived assets for fiscal 2024 was $377.00M, a 4.14% increase from fiscal 2023.
- WEST PHARMACEUTICAL SERVICES, INC. segment expenditure addition to long lived assets for fiscal 2023 was $362.00M, a 27.20% increase from fiscal 2022.
- WEST PHARMACEUTICAL SERVICES, INC. segment expenditure addition to long lived assets for fiscal 2022 was $284.60M, a 12.31% increase from fiscal 2021.
| Period end | Segment Expenditure Addition To Long Lived Assets 3 month | Segment Expenditure Addition To Long Lived Assets 6 month | Segment Expenditure Addition To Long Lived Assets 9 month | Segment Expenditure Addition To Long Lived Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.20M 10-Q · filed 2026-07-23 | $85.90M 10-Q · filed 2026-07-23 | $162.00M derived: sum of 3 quarters · filed 2026-07-23 | $225.30M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $42.70M 10-Q · filed 2026-04-23 | $118.80M derived: sum of 2 quarters · filed 2026-04-23 | $182.10M derived: sum of 3 quarters · filed 2026-04-23 | $257.30M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $76.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $139.40M derived: sum of 2 quarters · filed 2026-02-17 | $214.60M derived: sum of 3 quarters · filed 2026-07-23 | $285.90M 10-K · filed 2026-02-17 |
| 2025-09-30 | $63.30M 10-Q · filed 2025-10-23 | $138.50M derived: sum of 2 quarters · filed 2026-07-23 | $209.80M 10-Q · filed 2025-10-23 | $314.70M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $75.20M 10-Q · filed 2026-07-23 | $146.50M 10-Q · filed 2026-07-23 | $251.40M derived: sum of 3 quarters · filed 2026-07-23 | $332.70M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $71.30M 10-Q · filed 2026-04-23 | $176.20M derived: sum of 2 quarters · filed 2026-04-23 | $257.50M derived: sum of 3 quarters · filed 2026-04-23 | $357.70M derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $104.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $186.20M derived: sum of 2 quarters · filed 2026-02-17 | $286.40M derived: sum of 3 quarters · filed 2026-02-17 | $377.00M 10-K · filed 2026-02-17 |
| 2024-09-30 | $81.30M 10-Q · filed 2025-10-23 | $181.50M derived: sum of 2 quarters · filed 2025-10-23 | $272.10M 10-Q · filed 2025-10-23 | |
| 2024-06-30 | $100.20M 10-Q · filed 2025-07-24 | $190.80M 10-Q · filed 2025-07-24 | ||
| 2024-03-31 | $90.60M 10-Q · filed 2025-04-24 | |||
| 2023-12-31 | $362.00M 10-K · filed 2026-02-17 | |||
| 2022-12-31 | $284.60M 10-K · filed 2025-02-18 | |||
| 2021-12-31 | $253.40M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |
| GLAUKOS Corp (GKOS) | United States | $9.135B | -43.73 |
| MiniMed Group, Inc. (MMED) | United States | $5.748B | -16.85 |
| MERIT MEDICAL SYSTEMS INC (MMSI) | United States | $5.212B | 28.44 |
| TELEFLEX INC (TFX) | United States | $5.093B | -5.44 |